

Press Release

Profit before Tax up 36% to Rs 406 crores for the quarter

Net Profit up 35% to Rs 333 crores

Vadodara, October 22nd, 2020

Alembic Pharmaceuticals Limited reported its consolidated financial results for the quarter ending 30th September 2020.

Financial Highlights

- Net Sales for the quarter up 17% to Rs 1457 crores from Rs. 1241 crores.
- **Net Profit for the quarter up 35% to Rs 333 crores from Rs 246 crores.**
- Net sales for H-1 FY21 up 28% to Rs 2798 crores against Rs 2190 crores.
- **Net profit for H-1 FY21 up 72% to Rs 635 crores from Rs 370 crores.**

Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited said "It was a strong quarter for the company led by growth in the domestic business. The International as well as API Business also continued to perform well."

Operational Highlights

International Business

- International formulations grew 21% to Rs 779 crores in the quarter and 41% to Rs 1550 crores for H-1.
- US Generics grew 8% to Rs 582 crores in the quarter and 33% to Rs 1177 Crores for H-1.
- Ex-US International Formulations grew 84% to Rs 197 crores in the quarter and 73% to Rs 373 Crores for H-1.
- 6 ANDA approvals received during the quarter; 131 Cumulative ANDA approvals.
- 7 ANDA filings during the quarter; Cumulative ANDA filings at 198.

India Formulations Business

- India formulations business grew 6% to Rs 415 crores in the quarter and was Rs 721 crores for H-1.



ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. • TEL : (0265) 2280550, 2280880 • FAX : (0265) 2281229
website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123

API Business

- API business grew 29% to Rs 263 crores in the quarter and 40% to Rs 528 crores for H-1.
- 2 DMF were filed in the quarter.

Summary of Total Revenue is as under:


(Rs in Crores)

Particulars	Q2 FY21	Q2 FY20	% Change	H-1 FY21	H-1 FY19	% Change
Formulation						
USA	582	539	8%	1177	883	33%
Ex- US	197	107	84%	373	216	73%
India	415	391	6%	721	715	1%
API	263	204	29%	528	376	40%
Total	1457	1241	17%	2798	2190	28%

Summary of Profit is as under:

(Rs in Crores)

Particulars	Q2 FY21	Q2 FY20	% Change	H1 FY21	H1 FY20	% Change
EBITDA Pre R&D	628	505	24%	1177	836	41%
<i>EBITDA Pre R&D %</i>	43%	41%		42%	38%	
EBITDA Post R&D	455	342	33%	871	542	61%
<i>EBITDA Post R&D %</i>	31%	28%		31%	25%	



ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. • TEL : (0265) 2280550, 2280880 • FAX : (0265) 2281229
website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123

Profit Before Tax	406	299	36%	775	458	69%
Net Profit after Tax	333	246	35%	635	370	72%

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a marketing team of over 5000 are well recognized by doctors and patients.

Information about the company can be found at www.alembicpharmaceuticals.com;
(reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

For more information contact:

Ajay Kumar Desai Phone: +91 22 – 306 11681 Email: ajay.desai@alembic.co.in	Mitanshu Shah Phone: +91 265 – 3007630 Email: mitanshu.shah@alembic.co.in
---	---



ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. • TEL : (0265) 2280550, 2280880. • FAX : (0265) 2281229
website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123